Watson biological 13 valent pneumococcal conjugate vaccine approved in Russia

Watson biology announced on the evening of July 2nd that the company's 13 valent pneumococcal conjugate vaccine was approved by the Ministry of health of the Russian Federation to enter the clinical trial It is worth mentioning that the 13 valent pneumococcal conjugate vaccine is one of the first varieties that Watson biological has applied for registration overseas, and the progress of research and development has attracted the attention of the capital market Watson biological is mainly engaged in vaccine production and sales Under the increasingly competitive environment of domestic vaccine market, the company seeks to enter overseas to develop new development models In 2012, the company signed an agreement with Biomed of Russia to jointly complete the registration application of 13 valent pneumococcal conjugate vaccine in Russia After the product is approved, Biomed will exclusively purchase 13 valent pneumococcal conjugate vaccine stock solution from Watson bio for vaccine production In China, Watson biological's 13 valent pneumococcal polysaccharide conjugate vaccine is applying for clinical approval It is one of the company's heavyweight reserve varieties and has not been approved by any domestic enterprise Previously, Li Yunchun, chairman of the company, pointed out that the 13 valent pneumococcal polysaccharide conjugate vaccine is the highest coverage pneumonia conjugate vaccine at present, and the only one approved in the world that can be used for both infants and the elderly.